var data={"title":"Rotavirus vaccines for infants","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Rotavirus vaccines for infants</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/contributors\" class=\"contributor contributor_credentials\">David O Matson, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/contributors\" class=\"contributor contributor_credentials\">Teresa K Duryea, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 13, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus is the most common cause of severe, acute gastroenteritis in infants and children worldwide [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1-3\" class=\"abstract_t\">1-3</a>]. In the prevaccine era, rotavirus was estimated to cause approximately 440,000 deaths, 2 million hospitalizations, and 25 million outpatient visits per year worldwide among children &lt;5 years of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/2\" class=\"abstract_t\">2</a>].</p><p>More than 40 percent of World Health Organization member countries have introduced a <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> into their infant vaccination schedules [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/4\" class=\"abstract_t\">4</a>]. Other countries are documenting their rotavirus disease burden in preparation for introduction of a rotavirus vaccine.</p><p>Rotavirus vaccination of infants will be discussed below. The pathogenesis, clinical presentation, and diagnosis of rotavirus gastroenteritis are discussed separately, as are general measures to prevent viral gastroenteritis in children. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rotavirus-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of rotavirus infection&quot;</a> and <a href=\"topic.htm?path=acute-viral-gastroenteritis-in-children-in-resource-rich-countries-management-and-prevention\" class=\"medical medical_review\">&quot;Acute viral gastroenteritis in children in resource-rich countries: Management and prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3802518\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus is a double-stranded RNA virus in the <em>Reoviridae</em> family [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/3\" class=\"abstract_t\">3</a>]. The outer capsid contains two proteins that define rotavirus serotypes: a G protein (VP7) and a P protein (VP4) (<a href=\"image.htm?imageKey=PEDS%2F89606\" class=\"graphic graphic_figure graphicRef89606 \">figure 1</a>). Five G-P combinations account for approximately 90 percent of human rotaviruses circulating worldwide: G1P[8], G2P[4], G3P[8], G4P[8], and G9P[8], but serotype prevalence varies from time to time and from place to place for reasons that are not understood. It is plausible that the differences in composition of the two licensed vaccines will impose different pressures on serotype prevalence.</p><p class=\"headingAnchor\" id=\"H59637410\"><span class=\"h1\">ROTAVIRUS VACCINES</span></p><p class=\"headingAnchor\" id=\"H187918050\"><span class=\"h2\">Vaccine development</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines have been developed from animal rotavirus strains, human-animal rotavirus reassortants (genes from human and animal strains), attenuated human rotaviruses, and subunits of rotavirus virions [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/5-10\" class=\"abstract_t\">5-10</a>]. Reassortants are necessary because most human rotaviruses grow too poorly in cell culture for production of standard vaccine lots for large-scale immunization programs. Monovalent vaccines prepared from animal rotaviruses have not been promising in humans. Assessment of rotavirus subunit vaccine candidates have reached animal studies [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H187918043\"><span class=\"h2\">Vaccines licensed in the United States</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two live, attenuated oral rotavirus vaccines are licensed for use in the United States and other countries (<a href=\"image.htm?imageKey=PEDS%2F70478\" class=\"graphic graphic_table graphicRef70478 \">table 1</a>). The vaccines have similar efficacy and safety, and no preference for one over the other vaccine exists, with a few exceptions (eg, latex allergy) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,3,12,13\" class=\"abstract_t\">1,3,12,13</a>]. (See <a href=\"#H3800611\" class=\"local\">'Contraindications'</a> below and <a href=\"#H3799903\" class=\"local\">'Efficacy/effectiveness'</a> below and <a href=\"#H9\" class=\"local\">'Adverse events and safety'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pentavalent human-bovine rotavirus reassortant vaccine (RV5, PRV, RotaTeq)</strong> is based upon the bovine strain, WC3, which is naturally attenuated for humans but not broadly cross-protective. Each reassortant component contains a single gene derived from a human rotavirus strain encoding a major outer capsid protein from the most common human serotypes: G1, G2, G3, G4, and P1[8] (<a href=\"image.htm?imageKey=PEDS%2F89607\" class=\"graphic graphic_figure graphicRef89607 \">figure 2</a>). This vaccine induces homologous (ie, serotype-specific) protection against the common types of exposure, as well as the nonvaccine type G9 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Attenuated human </strong><a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a><strong> (RV1, HRV, Rotarix) </strong>is a monovalent vaccine derived from the most common human rotavirus serotype combination (G1P[8]) that has been attenuated by serial passage<em> </em>in cell culture (<a href=\"image.htm?imageKey=PEDS%2F89607\" class=\"graphic graphic_figure graphicRef89607 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/8\" class=\"abstract_t\">8</a>]. Observational studies of natural rotavirus infection suggest that infection with one serotype provides at least partial cross-protection against most other serotypes [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"headingAnchor\" id=\"H183587254\"><span class=\"h2\">Other vaccines</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Human-bovine reassortant vaccine (116E, ROTAVAC)</strong> &ndash; The 116E <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> is a nonpathogenic strain (G9P[11]) that occurs naturally in India. It contains a virus reassortant strain in which one gene was from a rotavirus strain naturally occurring in bovines (P[11]) and 10 genes were from a rotavirus strain naturally occurring in humans. Phase 3 clinical trials have been completed (demonstrating efficacy of 54 percent against severe rotavirus gastroenteritis) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/10\" class=\"abstract_t\">10</a>]. The 116E vaccine is licensed for use in India but not in other countries [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lamb </strong><a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> &ndash; A monovalent, G10P[12] oral rotavirus vaccine is licensed in China, where its effectiveness was demonstrated in a population-based study [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/18\" class=\"abstract_t\">18</a>]. However, a mouse study suggests that monovalent rotavirus vaccines are not sufficiently immunogenic against heterotypic strains for protection against rotavirus disease in China [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/17\" class=\"abstract_t\">17</a>]. Previous studies indicate that strain variation and induction of antibody response is well correlated in mice and humans [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Oral bovine rotavirus pentavalent vaccine (BRV-PV)</strong> &ndash; BRV-PV is a heat-stable bovine-human reassortant vaccine that contains serotypes G1, G2, G3, G4, and G9 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/4,20\" class=\"abstract_t\">4,20</a>]. It is administered in three doses at 6, 10, and 14 weeks. A randomized trial compared BRV-PV with placebo in 3508 Nigerian infants [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/4,20\" class=\"abstract_t\">4,20</a>]. Four weeks after the third dose, infants who received BRV-PV had fewer episodes of laboratory-confirmed, severe rotavirus gastroenteritis than those who received placebo (31 versus 87 episodes; efficacy of 67 percent, 95% CI 50-78 percent). The rates of adverse events were similar between groups. None of the participants had confirmed intussusception. BRV-PV is less expensive than RV5 and RV1 and may be more suitable for vaccination programs in remote areas where cold-chain capacity is limited [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/20\" class=\"abstract_t\">20</a>]. It is not yet licensed for use.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Oral human neonatal </strong><a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a><strong> (RV3-BB)</strong> &ndash; RV3-BB is a naturally attenuated oral vaccine developed from a strain initially recovered from an outbreak in a nursery in which infections were asymptomatic (G3P[6]) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/21\" class=\"abstract_t\">21</a>]. In a phase 2 randomized trial in Indonesia, RV3-BB was efficacious in preventing severe rotavirus gastroenteritis before age 18 months when administered to neonates (at age 0 to 5 days, 8 weeks, and 14 weeks) and infants (at age 8, 14, and 18 weeks). RV3-BB also appears to be safe and immunogenic [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tetravalent human-rhesus reassortant vaccine</strong> &ndash; An oral tetravalent human-rhesus rotavirus reassortant vaccine (RRV-TV, RotaShield) was licensed in 1998 and recommended for universal immunization of term infants in the United States, but was withdrawn from the market in 1999 because of an epidemiologic link to intussusception occurring within two weeks after vaccine administration [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/23-27\" class=\"abstract_t\">23-27</a>]. (See <a href=\"#H3801876\" class=\"local\">'Risk with RRV-TV'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H73761146\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend universal immunization of infants against rotavirus, as recommended by the Centers for Disease Control and Prevention, the World Health Organization, the American Academy of Pediatrics, the American Academy of Family Physicians, the European Society for Pediatric Infectious Diseases, and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,3,12,13\" class=\"abstract_t\">1,3,12,13</a>].</p><p>In randomized trials and meta-analyses, rotavirus vaccines are highly efficacious in preventing rotavirus gastroenteritis and rotavirus gastroenteritis-associated hospitalization and health care utilization [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28-30\" class=\"abstract_t\">28-30</a>]. (See <a href=\"#H3799903\" class=\"local\">'Efficacy/effectiveness'</a> below.)</p><p class=\"headingAnchor\" id=\"H3800611\"><span class=\"h1\">CONTRAINDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines are contraindicated in those infants [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,12,13,31-33\" class=\"abstract_t\">1,12,13,31-33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Who are allergic to any of the ingredients of the vaccine; attenuated human <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> is contraindicated in infants with severe (anaphylactic) allergy to latex because the applicator contains latex; pentavalent human-bovine rotavirus reassortant vaccine can be administered to such infants (see <a href=\"topic.htm?path=allergic-reactions-to-vaccines#H12\" class=\"medical medical_review\">&quot;Allergic reactions to vaccines&quot;, section on 'Latex'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Who had a severe (anaphylactic) allergic reaction after a previous dose</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With severe combined immunodeficiency (SCID) &ndash; Vaccine-acquired rotavirus disease has been reported in infants who subsequently were diagnosed with SCID [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/31,34-38\" class=\"abstract_t\">31,34-38</a>] (see <a href=\"topic.htm?path=severe-combined-immunodeficiency-scid-an-overview\" class=\"medical medical_review\">&quot;Severe combined immunodeficiency (SCID): An overview&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With a history of intussusception &ndash; Fatal intussusception after the second dose has been reported in infants with a history of intussusception after the first dose [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/32,39\" class=\"abstract_t\">32,39</a>]</p><p/><p>Although few data exist upon which to base recommendations, the 2013 Infectious Diseases Society of America guidelines on vaccination of the immunocompromised host consider the following conditions to also be contraindications to rotavirus vaccination because of the potential risk of serious adverse effects [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combined immunodeficiencies &ndash; Di George syndrome and other combined immunodeficiencies with a CD3 count &lt;500 <span class=\"nowrap\">cells/microL,</span> Wiskott-Aldrich syndrome, X-linked lymphoproliferative disease, and familial disorders that predispose to hemophagocytic lymphohistiocytosis (eg, Griscelli syndrome, Chediak-Higashi syndrome, Hermansky-Pudlak syndrome) (see <a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain phagocytic cell deficiencies &ndash; Leukocyte adhesion deficiency, defects of cytotoxic granule release (eg, Chediak-Higashi), and other undefined phagocytic cell defects (see <a href=\"topic.htm?path=leukocyte-adhesion-deficiency\" class=\"medical medical_review\">&quot;Leukocyte-adhesion deficiency&quot;</a> and <a href=\"topic.htm?path=chediak-higashi-syndrome\" class=\"medical medical_review\">&quot;Chediak-Higashi syndrome&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major antibody deficiencies treated with immunoglobulin therapy (see <a href=\"topic.htm?path=primary-humoral-immunodeficiencies-an-overview\" class=\"medical medical_review\">&quot;Primary humoral immunodeficiencies: An overview&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Planned or status-post hematopoietic stem cell transplant</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Planned or current receipt of cancer chemotherapy</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Status-post solid organ transplant</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic inflammatory disease treated with immunosuppressive medications (ie, <a href=\"topic.htm?path=prednisone-pediatric-drug-information\" class=\"drug drug_pediatric\">prednisone</a>, <a href=\"topic.htm?path=azathioprine-pediatric-drug-information\" class=\"drug drug_pediatric\">azathioprine</a>, 6-mercaptopurine, biologic agents [eg, tumor necrosis factor antagonists, <a href=\"topic.htm?path=rituximab-intravenous-pediatric-drug-information\" class=\"drug drug_pediatric\">rituximab</a>])</p><p/><p>These conditions are uncommon to rare among infants in the age group for <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> administration (six weeks to eight months). (See <a href=\"#H6\" class=\"local\">'Schedule'</a> below.)</p><p>The following conditions are <strong>not</strong> contraindications to rotavirus vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,33\" class=\"abstract_t\">1,13,33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunocompromised family member or household member (see <a href=\"#H3802933\" class=\"local\">'Immunocompromised household contact'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Breastfeeding (efficacy trials included breastfeeding infants, with no alteration in normal breastfeeding patterns) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/40,41\" class=\"abstract_t\">40,41</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnant family member or household contact</p><p/><p class=\"headingAnchor\" id=\"H3800659\"><span class=\"h1\">PRECAUTIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Immunodeficiency other than severe combined immunodeficiency (SCID)</strong> &ndash; Decisions regarding immunization of children with known or suspected immunodeficiency other than SCID (which is a contraindication to <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>) should be made on a case-by-case basis after considering the risks and benefits; however, there are few data regarding the efficacy or safety of rotavirus vaccine to infants who are potentially immunocompromised.</p><p/><p class=\"bulletIndent1\">In this setting, the United States Advisory Committee on Immunization Practices (ACIP) advises consultation with an immunologist or infectious disease specialist and the American Academy of Pediatrics advises precaution for administration of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> for manifestations of altered immunocompetence other than SCID [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,31\" class=\"abstract_t\">1,13,31</a>]. The 2013 Infectious Diseases Society of America (IDSA) guidelines on vaccination of the immunocompromised host suggest that rotavirus vaccine may be administered to infants with the following conditions [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"abstract_t\">33</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Human immunodeficiency virus (HIV) exposure or infection &ndash; Rotavirus gastroenteritis may be particularly severe in HIV-infected children. In a prospective study in South Africa, HIV-infected children were more likely to have a prolonged hospitalization and had a fourfold increased mortality rate compared with HIV-uninfected children admitted to the same hospital [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/42\" class=\"abstract_t\">42</a>].</p><p/><p class=\"bulletIndent2\"><a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Rotavirus vaccine</a> trials that included HIV-infected infants have found no evidence of enhanced disease in HIV-infected children [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"abstract_t\">33</a>]. In randomized trials, administration of attenuated human rotavirus vaccine (RV1) and pentavalent human-bovine rotavirus reassortant vaccine (RV5) was safe and immunogenic when administered to HIV-positive infants in a three-dose schedule [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p/><p class=\"bulletIndent2\">Groups other than the IDSA (eg, the Department of Health and Human Services, Centers for Disease Control and Prevention, American Academy of Pediatrics) suggest that the potential risks and benefits of rotavirus vaccination be considered before vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/45\" class=\"abstract_t\">45</a>]; however, they suggest that the potential delay in establishment of definitive diagnosis of HIV infection beyond the recommended age for the first dose of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> and considerable attenuation of rotavirus vaccine strains support vaccination of HIV-exposed and infected infants.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary (congenital) complement deficiencies. (See <a href=\"topic.htm?path=inherited-disorders-of-the-complement-system\" class=\"medical medical_review\">&quot;Inherited disorders of the complement system&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chronic granulomatous disease. (See <a href=\"topic.htm?path=chronic-granulomatous-disease-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Congenital or cyclic neutropenia. (See <a href=\"topic.htm?path=congenital-neutropenia\" class=\"medical medical_review\">&quot;Congenital neutropenia&quot;</a> and <a href=\"topic.htm?path=cyclic-neutropenia\" class=\"medical medical_review\">&quot;Cyclic neutropenia&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Immunoglobulin A deficiency, provided that all other components of the immune system are normal. (See <a href=\"topic.htm?path=selective-iga-deficiency-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">&quot;Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Specific polysaccharide antibody deficiency provided that all other components of the immune system are normal. (See <a href=\"topic.htm?path=specific-antibody-deficiency\" class=\"medical medical_review\">&quot;Specific antibody deficiency&quot;</a>.)</p><p/><p class=\"bulletIndent1\">For infants with innate immune defects that result in defects of cytokine generation or response or cellular activation (eg, defects of the <span class=\"nowrap\">interferon-gamma/interleukin-12</span> axis), the IDSA recommends consultation with a specialist before administration of live vaccines [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other precautions</strong> &ndash; The ACIP and American Academy of Pediatrics suggest the following conditions are precautions for the administration of rotavirus vaccines, because the safety and efficacy of the vaccine were not specifically evaluated in infants with these conditions [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Acute moderate-to-severe gastroenteritis &ndash; Immunization of infants with acute, moderate-to-severe gastroenteritis should be deferred until the illness resolves. A concern is that the antibody response may be diminished.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Moderate-to-severe febrile illness &ndash; Immunization of infants with moderate to severe illness of any type should be deferred until the illness resolves. Deferral of the immunization makes it easier to differentiate possible adverse effects related to the vaccine from manifestations of the underlying disease.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Pre-existing or acquired chronic gastrointestinal disease excluding intussusception &ndash; Infants with pre-existing or acquired gastrointestinal conditions (eg, congenital malabsorption syndromes, Hirschsprung disease, short-bowel syndrome, some forms of cystic fibrosis-related gastrointestinal disease) who are not receiving immunosuppressive therapy should benefit from rotavirus vaccines, and the benefits outweigh the theoretic risks. In a pilot study, RV1 appeared to be safe and immunogenic in 14 children with early intestinal failure [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/46\" class=\"abstract_t\">46</a>]. In another small study, RV5 appeared to be safe and immunogenic in five infants with a history of bowel resection [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Spina bifida or bladder exstrophy &ndash; Infants with spina bifida or bladder exstrophy have a high risk of developing latex allergy. To minimize latex exposure, some experts suggest that RV5 be used for such infants because the applicator is latex-free. If RV5 is not available, the ACIP recommends that RV1 be used because the benefit of vaccination is greater than the risk of sensitization [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">SCHEDULE</span></p><p class=\"headingAnchor\" id=\"H500915636\"><span class=\"h2\">Routine schedule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The recommended routine schedules for pentavalent human-bovine rotavirus reassortant vaccine (RV5) and attenuated human <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (RV1) differ [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>RV5 is administered in three oral doses at two, four, and six months of age.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>RV1 is administered in two oral doses at two and four months.</p><p/><p>Whenever possible, the <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> series should be completed with the same vaccine product [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>]; however, vaccination should not be deferred if the product used for previous doses is not known. A total of three doses of vaccine should be given to infants who received RV5 for any dose and infants in whom the vaccine product for previous dose(s) is unknown.</p><p>An open-label, multicenter randomized trial confirmed that completion of rotavirus immunization using a combination of RV5 and RV1 was as immunogenic as completion with RV5 or RV1 and was well tolerated [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/48\" class=\"abstract_t\">48</a>]. In postlicensure surveillance, completion of immunization with a combination of RV5 and RV1 (eg, two doses of RV5 and one dose of RV1 or two doses of RV1 and one dose of RV5) was 80 percent (95% CI 51-92 percent) effective in preventing rotavirus gastroenteritis [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/49\" class=\"abstract_t\">49</a>]. Although mixed schedules and single formulation schedules were not directly compared, this is similar to published rates of effectiveness for three doses of RV5 or two doses of RV1 in the same population [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H500915643\"><span class=\"h2\">Catch-up schedule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The catch-up schedules for RV5 and RV1 differ:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>RV5</strong> &ndash; In the United States, the first dose of RV5 should be given between 6 and 15 weeks of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Two subsequent doses are administered with a minimum interval of four weeks between doses [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/51\" class=\"abstract_t\">51</a>]. The third dose should not be administered after eight months, zero days of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>].</p><p/><p class=\"bulletIndent1\">The vaccine series should not be initiated in infants who are older than 14 weeks, 6 days of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>]. The safety of the first dose of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> in older infants was not studied in the prelicensure trials; however, for infants in whom the first dose is inadvertently administered at 15 weeks or older, the rest of the rotavirus immunization series should be completed as described above [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>]. The timing of the first dose should not affect the safety and efficacy of the second and third dose.</p><p/><p class=\"bulletIndent1\">In Europe, the first dose of RV5 should be given between 6 and 12 weeks, preferably at 6 to 8 weeks, and the full schedule completed by 24 weeks of age, but preferably earlier [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>RV1</strong> &ndash; In the United States, the first dose of RV1 should be given between 6 and 15 weeks of age and the full schedule completed by eight months, zero days of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>].</p><p/><p class=\"bulletIndent1\">In Europe, the first dose of RV1 should be given between 6 and 12 weeks, preferably at 6 to 8 weeks, and the full schedule completed by 24 weeks of age, but preferably earlier [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p>There is no maximum interval between doses.</p><p class=\"headingAnchor\" id=\"H500915613\"><span class=\"h2\">Special circumstances</span></p><p class=\"headingAnchor\" id=\"H500915621\"><span class=\"h3\">Premature infants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, rotavirus vaccines can be administered to premature infants who are clinically stable, at least six weeks old, and are going to be or have been discharged from the nursery [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,52,53\" class=\"abstract_t\">1,13,52,53</a>]. The European Society for Paediatric Infectious Diseases and the Australian government recommend rotavirus vaccination of premature infants according to their chronologic age, whether or not they have been discharged from the nursery, with appropriate precautions to prevent transmission to high-risk contacts [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/12,54\" class=\"abstract_t\">12,54</a>]. (See <a href=\"#H12\" class=\"local\">'Shedding and transmission of vaccine virus'</a> below.)</p><p>In retrospective reviews, age-appropriate administration of RV5 to preterm enterally-fed infants in the neonatal intensive care unit was well tolerated and did not appear to be associated with transmission [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/55,56\" class=\"abstract_t\">55,56</a>]. Subsequent prospective studies support the low risk of transmission [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/57,58\" class=\"abstract_t\">57,58</a>]. The larger prospective study evaluated rotavirus shedding and transmission among infants age &lt;15 weeks admitted to an intensive care unit with single or double room assignments of an academic medical center that permitted RV5 administration during hospitalization [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/57\" class=\"abstract_t\">57</a>]. Rotavirus was detected in 13 of 1192 stool specimens (1.1 percent) collected weekly: one wild-type strain from an unvaccinated infant and 12 vaccine-type strains from nine vaccinated infants. No vaccine-type rotavirus cases were observed among unvaccinated infants during 1952 days of potential exposure, and no reassortants were identified. These findings suggest that delaying RV5 vaccination until hospital discharge may be unnecessary in hospitals with comparable infection control standards. In making decisions for individual infants, attending clinicians must consider the benefit of vaccination with possible asymptomatic transmission and the risk of missed opportunity for rotavirus vaccination.</p><p class=\"headingAnchor\" id=\"H500915629\"><span class=\"h3\">Infants with rotavirus gastroenteritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> series should be initiated or completed in infants who have had rotavirus gastroenteritis before receiving the full two- or three-dose series because natural first infections do not provide complete immunity against subsequent severe disease and multiple serotypes of rotavirus usually are present in any community [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,59\" class=\"abstract_t\">1,13,59</a>].</p><p class=\"headingAnchor\" id=\"H3801215\"><span class=\"h3\">Receipt of blood products</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines may be administered at any time in relation to the receipt of blood products, including antibody-containing products [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,60\" class=\"abstract_t\">1,60</a>].</p><p class=\"headingAnchor\" id=\"H3802185\"><span class=\"h3\">Hospitalization of vaccinated infant</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the event that an infant requires hospitalization after administration of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>, standard precautions should be used to prevent the spread of vaccine virus in the hospital setting [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/13\" class=\"abstract_t\">13</a>]. No additional infection control measures are necessary. Co-rooming with children with severe combined immunodeficiency or suspected severe immunodeficiency is not recommended. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H2\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Standard precautions'</a> and <a href=\"#H12\" class=\"local\">'Shedding and transmission of vaccine virus'</a> below.)</p><p class=\"headingAnchor\" id=\"H3802933\"><span class=\"h3\">Immunocompromised household contact</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines can be administered to infants living in households with immunocompromised persons [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,33\" class=\"abstract_t\">1,13,33</a>]. (See <a href=\"#H12\" class=\"local\">'Shedding and transmission of vaccine virus'</a> below.)</p><p class=\"headingAnchor\" id=\"H3927504007\"><span class=\"h3\">Resource-poor countries with high child mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The World Health Organization recommends routine rotavirus vaccination for all its member countries [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/4\" class=\"abstract_t\">4</a>]. <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Rotavirus vaccine</a> effectiveness varies among the countries that have introduced a rotavirus vaccine into the routine infant immunization schedule [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/61-69\" class=\"abstract_t\">61-69</a>]. Although poverty is a surrogate marker for poorer population vaccine effectiveness [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/70-73\" class=\"abstract_t\">70-73</a>], rotavirus vaccine remains effective in reducing rotavirus-related hospitalization and emergency department visits in resource-poor countries with high child mortality [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/74,75\" class=\"abstract_t\">74,75</a>]. (See <a href=\"#H3799903\" class=\"local\">'Efficacy/effectiveness'</a> below.)</p><p>Factors that may explain variation in vaccine effectiveness include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater portion of missed vaccination opportunities, related to the narrow age range for administration [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/67,69\" class=\"abstract_t\">67,69</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Failure to adopt a universal recommendation for rotavirus vaccination (which may prevent or reduce herd immunity) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/76,77\" class=\"abstract_t\">76,77</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Variation in herd effect with increasing interval from initiation of universal vaccination with high uptake [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/63,78,79\" class=\"abstract_t\">63,78,79</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Relatively increased natural, wild-type rotavirus circulation, reducing <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> effectiveness with increasing interval from initiation of universal vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/65,80-82\" class=\"abstract_t\">65,80-82</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Naturally acquired rotavirus disease in infants too young to be vaccinated [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/62\" class=\"abstract_t\">62</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Attenuation of vaccine response by transplacental maternal antibody [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/83\" class=\"abstract_t\">83</a>] or in infants who are exclusively breast-fed [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/84\" class=\"abstract_t\">84</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malnutrition or poor diet (which may affect the intestinal biome) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/62,85,86\" class=\"abstract_t\">62,85,86</a>]</p><p/><p class=\"headingAnchor\" id=\"H3803151\"><span class=\"h1\">ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines are administered orally [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>]. Each dose of pentavalent human-bovine rotavirus reassortant vaccine (RV5) is 2 mL (<a href=\"image.htm?imageKey=PEDS%2F70478\" class=\"graphic graphic_table graphicRef70478 \">table 1</a>). Each dose of attenuated human <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (RV1) is 1 mL. To avoid loss of a portion of the dose and of splashes into the eyes of infants, parents, or health care providers, the vaccine should be administered gently inside the cheek [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/87\" class=\"abstract_t\">87</a>].</p><p>Dietary restriction, including breastfeeding, is not needed before or after <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> is administered. Doses that are regurgitated, spit out, or vomited need not be repeated (they were not repeated in prelicensure studies of efficacy) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,60\" class=\"abstract_t\">1,13,60</a>]. Multiple randomized trials have demonstrated that breastfeeding does not affect rotavirus vaccine efficacy; normal breastfeeding was not altered in the prelicensure trials [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28,30,40,41\" class=\"abstract_t\">28,30,40,41</a>]. In randomized trials that specifically evaluated this issue, immune response was not affected by abstaining from breastfeeding for &ge;1 hour before and after each dose of rotavirus vaccine [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/88-90\" class=\"abstract_t\">88-90</a>].</p><p>In the event that <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> is injected rather than administered orally, the dose is not considered valid and should be repeated within the appropriate age and dosing schedule [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/87\" class=\"abstract_t\">87</a>].</p><p class=\"headingAnchor\" id=\"H3803158\"><span class=\"h1\">ADMINISTRATION WITH OTHER VACCINES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus vaccines can be administered at the same visit as the other routine infant immunizations [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1,13,91,92\" class=\"abstract_t\">1,13,91,92</a>].</p><p>Simultaneous administration of oral polio vaccine (OPV) may be associated with decreased immune response to the first dose of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>, but this interference does not persist after subsequent doses [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/3,93-96\" class=\"abstract_t\">3,93-96</a>].</p><p>The United States Advisory Committee on Immunization Practices suggests that <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> can be administered simultaneously or at any interval before or after other injectable or intranasal live vaccines [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/60\" class=\"abstract_t\">60</a>]. The American Academy of Pediatrics suggests that rotavirus vaccine can be administered concurrently with other childhood vaccines [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/13\" class=\"abstract_t\">13</a>]. In countries where OPV continues to be used, the European Society for Pediatric Infectious Disease and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition suggest that rotavirus vaccines and OPV not be administered at the same visit [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H3799903\"><span class=\"h1\">EFFICACY/EFFECTIVENESS</span></p><p class=\"headingAnchor\" id=\"H3799910\"><span class=\"h2\">Rotavirus gastroenteritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The protection against rotavirus gastroenteritis provided by the two licensed vaccines is similar to that observed following natural infection [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/59\" class=\"abstract_t\">59</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Overall effectiveness</strong> &ndash; The effectiveness of rotavirus immunization is difficult to determine because many children with rotavirus gastroenteritis do not seek medical attention; however, the number of stool samples sent for rotavirus testing and the number of positive samples can serve as a marker of vaccine effectiveness. Such laboratory surveillance indicates that during each rotavirus season since reintroduction of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> in the United States in 2006, rotavirus activity was delayed in onset and diminished in magnitude compared with the 2000-2006 rotavirus seasons (<a href=\"image.htm?imageKey=PEDS%2F58821\" class=\"graphic graphic_figure graphicRef58821 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/97-99\" class=\"abstract_t\">97-99</a>]. A pattern of alternating reduced and markedly reduced seasonality has occurred from 2007-2008 through the 2013-2014 rotavirus seasons.</p><p/><p class=\"bulletIndent1\">In a systematic review of 57 observational studies from 27 countries, rotavirus immunization reduced rotavirus-related hospitalization and emergency department visits among children &lt;5 years by 67 percent [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/74\" class=\"abstract_t\">74</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Efficacy and effectiveness of</strong> <strong>RV5</strong> &ndash; In randomized trials and meta-analyses, pentavalent human-bovine rotavirus reassortant vaccine (RV5) was efficacious in preventing rotavirus gastroenteritis, rotavirus gastroenteritis hospitalization, and rotavirus gastroenteritis-associated health care utilization in infants [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28,29,100,101\" class=\"abstract_t\">28,29,100,101</a>]. In the largest trial comparing RV5 with placebo (the Rotavirus Efficacy and Safety Trial), 68,038 healthy infants from 11 countries were randomly assigned to receive three doses of vaccine or placebo at 4- to 10-week intervals [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28\" class=\"abstract_t\">28</a>]. The following results were reported:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the first rotavirus season after immunization, efficacy against severe G1-G4 rotavirus gastroenteritis (defined by an established clinical score based upon intensity and duration of symptoms [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/9\" class=\"abstract_t\">9</a>]) was 98 percent (95% CI 88-100 percent) and against G1-G4 rotavirus gastroenteritis of any severity was 74 percent (95% CI 67-80 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>RV5 reduced hospitalization for G1-G4 rotavirus gastroenteritis by 96 percent (95% CI 90-98 percent) and for any gastroenteritis by 59 percent (95% CI 52-65 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>RV5 reduced emergency department visits related to G1-G4 rotavirus gastroenteritis by 94 percent (95% CI 89-96 percent) and clinic visits by 86 percent (95% CI 74-93 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the second rotavirus season after immunization, the efficacy against severe rotavirus gastroenteritis was 88 percent (95% CI 49-99 percent) and against rotavirus gastroenteritis of any severity was 63 percent (95% CI 44-75 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In an extension study of 20,736 original participants followed for up to 3.1 years after the last dose of RV5, the efficacy against hospitalization and emergency department visits related to rotavirus gastroenteritis of any serotype was 94 percent (95% CI 91-96 percent) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/102\" class=\"abstract_t\">102</a>].</p><p/><p class=\"bulletIndent1\">In a systematic review of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> effectiveness from 2006 to 2016, the median effectiveness of RV5 in preventing rotavirus hospitalizations, emergency department visits, and outpatient visits was 90 percent (range 63 to 100 percent) in 20 studies from countries with low child mortality and 45 percent (range 43 to 92 percent) in seven studies from countries with high child mortality [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/75\" class=\"abstract_t\">75</a>]. RV5 protection appears to be sustained through the first four years of life [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/50,103,104\" class=\"abstract_t\">50,103,104</a>]. (See <a href=\"#H3927504007\" class=\"local\">'Resource-poor countries with high child mortality'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Efficacy and effectiveness of</strong> <strong>RV1</strong> &ndash; In randomized trials and meta-analyses, attenuated human <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (RV1) is efficacious in preventing rotavirus gastroenteritis, rotavirus gastroenteritis hospitalizations, and rotavirus-gastroenteritis-associated health care utilization in infants [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/29,30,101,105-110\" class=\"abstract_t\">29,30,101,105-110</a>]. In the largest trial comparing RV1 with placebo, 63,225 healthy infants from 11 countries in Latin America and Finland were randomly assigned to receive RV1 or placebo at two and four months of age [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/30\" class=\"abstract_t\">30</a>]. Episodes of severe gastroenteritis were identified by active surveillance of 20,169 infants from two weeks after the second dose until one year of age. Severe gastroenteritis was defined by the passage of &ge;3 loose or watery stools within a 24-hour period, with or without vomiting, that required overnight hospitalization or rehydration therapy in a medical facility. The following results were noted:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The efficacy against severe rotavirus gastroenteritis was 85 percent (95% CI 72-92 percent) and against severe gastroenteritis from any cause was 40 percent (95% CI 28-50 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The efficacy against gastroenteritis caused by G1P[8] strains was 92 percent (95% CI 74-98 percent) and against strains sharing only the P[8] antigen (G3P[8], G4P[8], G9P[8]) was 87 percent.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The efficacy against hospitalization for rotavirus gastroenteritis was 85 percent (95% CI 70-94 percent) and against hospitalization for gastroenteritis from any cause was 42 percent (95% CI 29-53 percent).</p><p/><p class=\"bulletIndent1\">The efficacy of RV1 during the first two years of life was assessed in a subgroup of patients and found to be similar to that during the first year [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/110\" class=\"abstract_t\">110</a>].</p><p/><p class=\"bulletIndent1\">In a systematic review of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> effectiveness from 2006 to 2016, the median effectiveness of RV1 in preventing rotavirus hospitalizations, emergency department visits, and outpatient visits was 84 percent (range 19 to 97 percent) in 13 studies from countries with low child mortality, 75 percent (range -2 to 94 percent) in eight studies from countries with medium child mortality, and 57 percent (range 18 to 69 percent) in nine studies from countries with high child mortality [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/75\" class=\"abstract_t\">75</a>]. Protection appears to be sustained for at least two years [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/50,75,104,111,112\" class=\"abstract_t\">50,75,104,111,112</a>]. (See <a href=\"#H3927504007\" class=\"local\">'Resource-poor countries with high child mortality'</a> above.)</p><p/><p class=\"bulletIndent1\">RV1 also appears to provide protection against G2P[4], which shares neither the G1 nor the P[8] antigen [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/111\" class=\"abstract_t\">111</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Incomplete immunization</strong> &ndash; A systematic review of postlicensure studies (2006 to 2016) found that incomplete immunization with RV5 or RV1 was effective in preventing rotavirus health care utilization but less effective than complete immunization [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/75\" class=\"abstract_t\">75</a>].</p><p/><p class=\"headingAnchor\" id=\"H1305954013\"><span class=\"h2\">Reduced risk of seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Rotavirus vaccine</a> appears to reduce the risk of seizures [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/113-116\" class=\"abstract_t\">113-116</a>]. Among a cohort of 250,601 infants monitored between 2006 and 2009 in the Vaccine Safety Datalink, rotavirus immunization was associated with an approximately 20 percent reduction (risk ratio 0.79, 95% CI 0.71-0.88) in the risk of seizures resulting in emergency department visit or hospitalization in the year following completion of the vaccination series [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/113\" class=\"abstract_t\">113</a>].</p><p class=\"headingAnchor\" id=\"H3799917\"><span class=\"h2\">Community (&quot;herd&quot;) immunity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus immunization in infants is associated with reduced rotavirus morbidity among unvaccinated neonates and young infants too young for vaccination, older children, and adults (ie, indirect protection or community [&quot;herd&quot;] immunity) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/117-127\" class=\"abstract_t\">117-127</a>]. Seventy percent vaccine uptake by 2010 has significantly altered natural rotavirus disease peaks in most of the United States [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/97,118\" class=\"abstract_t\">97,118</a>]. Even partial (approximately 50 percent) uptake of RV5 under a recommendation for universal immunization of infants with <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> was associated with reduced rotavirus disease in unvaccinated older children and adults [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/119-123\" class=\"abstract_t\">119-123</a>]. As an example, compared with 2006, rates of hospitalization for rotavirus infection in 2008 were reduced among children younger than three years, whether or not they were vaccinated [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/120\" class=\"abstract_t\">120</a>]. An 87 percent reduction occurred in the 6- to 11-month age group (with vaccine coverage 77 percent), a 96 percent reduction occurred in the 12- to 23-month age group (vaccine coverage 46 percent), and a 92 percent reduction occurred in the 24- to 35-month age group (vaccine coverage 1 percent). Similar results were observed at several and widely dispersed sites in North America [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/118-120,123,124\" class=\"abstract_t\">118-120,123,124</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">ADVERSE EVENTS AND SAFETY</span></p><p class=\"headingAnchor\" id=\"H73761326\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus immunization is safe. In prelicensure studies, the rates of death (&lt;0.1 percent) and serious adverse events (approximately 2.5 percent) were similar among vaccine and placebo recipients [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28,30\" class=\"abstract_t\">28,30</a>]. Vaccine and placebo recipients also reported similar rates of solicited events, including of fever (approximately 42 percent), vomiting (approximately 13 percent), and diarrhea (approximately 19 percent), all of which were mild [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Intussusception</span></p><p class=\"headingAnchor\" id=\"H3801443\"><span class=\"h3\">Risk with RV5 and RV1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intussusception is a rare potential adverse effect of oral rotavirus vaccination, estimated to occur in approximately 1 in 20,000 to 1 in 100,000 vaccine recipients [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/128-134\" class=\"abstract_t\">128-134</a>]. A history of intussusception is a contraindication to rotavirus vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/32,135\" class=\"abstract_t\">32,135</a>], yet for infants without a history of intussusception, the risk of intussusception after rotavirus vaccination is much lower than the risk of severe rotavirus gastroenteritis in children who do not receive <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/136-140\" class=\"abstract_t\">136-140</a>].</p><p>Parents should contact their child's health care provider if the child develops signs of intussusception (ie, stomach pain, vomiting, diarrhea, blood in the stool, or change in bowel habits) any time after vaccination, but especially within the first 14 days after a dose was given [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/141\" class=\"abstract_t\">141</a>]. (See <a href=\"topic.htm?path=intussusception-in-children#H9\" class=\"medical medical_review\">&quot;Intussusception in children&quot;, section on 'Clinical manifestations'</a>.)</p><p>Prelicensure studies of pentavalent human-bovine rotavirus reassortant vaccine (RV5) and attenuated human <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (RV1) found no increased risk of intussusception among vaccine recipients compared with placebo recipients [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28,30\" class=\"abstract_t\">28,30</a>]; however, postlicensure studies conducted by the Centers for Disease Control and Prevention (CDC), the Vaccine Safety Datalink investigation group, the US Food and Drug Administration (Post-licensure Rapid Immunization Safety Monitoring), vaccine manufacturers, and others suggest a rare association between RV5 and RV1 vaccination and intussusception within 21 days of the first dose [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/128-134,142,143\" class=\"abstract_t\">128-134,142,143</a>].</p><p>Nonetheless, the absolute number of estimated rotavirus hospitalizations prevented by rotavirus vaccines far exceeds that of cases of intussusception associated with <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (eg, 65,000 hospitalizations prevented and 40 to 120 cases of intussusception per year in the United States) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/136\" class=\"abstract_t\">136</a>]. The CDC continues to recommend universal rotavirus vaccine for infants in the United States.</p><p class=\"headingAnchor\" id=\"H3801876\"><span class=\"h3\">Risk with RRV-TV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In 1999, just over a year after human-rhesus rotavirus reassortant vaccine (RRV-TV, RotaShield) was licensed, it was withdrawn from the market because of a strong epidemiologic link to intussusception [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/24-27\" class=\"abstract_t\">24-27</a>]. The increased risk was estimated to be approximately 22-fold over the background risk within five to seven days of vaccination and overall approximately one excess case for every 10,000 to 12,000 infants vaccinated [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/26,144\" class=\"abstract_t\">26,144</a>].</p><p>The mechanism of this association is unclear. One hypothesis is that vaccination triggered intussusception in infants who were likely to develop intussusception with any enteric infection, based upon the observation that rates of intussusception were actually lower among vaccine recipients than nonvaccinees in the period 4 to 12 weeks after vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/27\" class=\"abstract_t\">27</a>]. Thus, RRV-TV may have caused intussusception in infants who otherwise would not have experienced intussusception, but it also may have protected against natural rotavirus infection-induced intussusception in others.</p><p>Rotavirus strain differences appear to make a difference in intussusception risk, as demonstrated by the reduced intussusception risk after RV5 or RV1 compared with RRV, and supported by results in a mouse model [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/145\" class=\"abstract_t\">145</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Kawasaki disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cases of Kawasaki disease were reported during clinical trials of rotavirus vaccines and in postmarketing surveillance [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/135,146,147\" class=\"abstract_t\">135,146,147</a>]; however, the number of cases of Kawasaki disease reported after administration of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> did not exceed the number of cases that would be expected to occur in infants who did not receive rotavirus vaccine, and there is no known cause-and-effect relationship between rotavirus vaccine and Kawasaki disease [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/135,147,148\" class=\"abstract_t\">135,147,148</a>].</p><p>Parents should contact their child's health care provider if the child develops signs of Kawasaki disease (eg, fever, conjunctivitis, erythema of the lips and oral mucosa, rash, swelling of the hands and feet, cervical lymphadenopathy), whether or not the child recently received <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>. (See <a href=\"topic.htm?path=kawasaki-disease-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Kawasaki disease: Clinical features and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Shedding and transmission of vaccine virus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rotavirus shedding in the stool peaks within approximately seven days of administration and is most common after the first dose [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/135,149-151\" class=\"abstract_t\">135,149-151</a>]. Viral shedding may be prolonged in infants with immunodeficiency [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/35,152\" class=\"abstract_t\">35,152</a>]. Transmission of vaccine virus resulting in symptomatic gastroenteritis is known from three case reports [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/153-155\" class=\"abstract_t\">153-155</a>]; separately, zero of 100 participants in a placebo-controlled twin study experienced symptomatic transmission of RV1 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/156\" class=\"abstract_t\">156</a>].</p><p>To minimize the risk of vaccine-derived rotavirus infections transmitted by the fecal-oral route, individuals who care for infants should wash their hands after changing a diaper. Particular care should be taken with this precaution for at least one week after the first dose. Highly immunocompromised individuals should avoid handling diapers of infants who have received <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> for at least four weeks after vaccination [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"abstract_t\">33</a>]. Highly immunocompromised individuals include (but are not limited to) those with combined primary immunodeficiency; receiving cancer chemotherapy; within two months of solid organ transplant; with HIV infection and CD4 count &lt;200 <span class=\"nowrap\">cells/microL</span> (adults and adolescents) or CD4 percentage &lt;15 percent (infants and children); receiving daily glucocorticoid therapy for &ge;14 days at a dose equivalent to <a href=\"topic.htm?path=prednisone-pediatric-drug-information\" class=\"drug drug_pediatric\">prednisone</a> &ge;20 <span class=\"nowrap\">mg/day</span> or &gt;2 <span class=\"nowrap\">mg/kg</span> per day, if they weigh &lt;10 kg.</p><p>In the phase 3 prelicensure trial of RV5, 9 percent of subjects who were evaluated had fecal shedding of vaccine virus four to six days after the first dose [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/149,151\" class=\"abstract_t\">149,151</a>]. None and 0.3 percent of recipients shed vaccine virus four to six days after the second and third dose, respectively. In studies of RV1, 50 to 80 percent of infants shed vaccine virus approximately one week and 24 percent at approximately one month after the first dose [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/157\" class=\"abstract_t\">157</a>]. After the second dose, between 4 and 18 percent of recipients shed virus at one week and 1.2 percent at approximately one month.</p><p>Transmission of vaccine virus has not been well studied; it appears to occur more frequently among recipients of RV1 than RV5 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/150\" class=\"abstract_t\">150</a>]; however, it rarely results in symptoms. In a randomized trial, in which one twin in each of 100 twin pairs received two doses of RV1 and the other twin received placebo, transmission of vaccine virus occurred in 15 of 80 evaluable cases (18.8 percent) but was not associated with symptomatic gastroenteritis [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/156\" class=\"abstract_t\">156</a>]. Such asymptomatic transmission may contribute to community (&quot;herd&quot;) immunity [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/150\" class=\"abstract_t\">150</a>]. (See <a href=\"#H3799917\" class=\"local\">'Community (&quot;herd&quot;) immunity'</a> above.)</p><p class=\"headingAnchor\" id=\"H4184606107\"><span class=\"h2\">G serotype substitution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Observational studies suggest that pressure from mass immunization with RV5 or RV1 may alter the prevailing rotavirus serotypes (eg, G12 may persist or predominate in areas where RV1 or RV5 is the predominant immunogen, G2 may persist or predominate where RV1 is the predominant immunogen) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/67,68,80,158-162\" class=\"abstract_t\">67,68,80,158-162</a>]. Mass immunization may reduce the incidence of simultaneous infectious with multiple rotavirus types, &quot;mixed infections&quot; [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H3803400\"><span class=\"h2\">Reporting adverse events</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, any clinically significant or unexpected adverse events that occur after administration of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (including intussusception and Kawasaki disease) should be reported to the <a href=\"http://vaers.hhs.gov/index&amp;token=dJuRidyjQYZxq9fkueW6qyWTvn/p9jDJLlDYcIYjX1yIn9pmTuN0f+LI7X4NwNtw&amp;TOPIC_ID=6023\" target=\"_blank\" class=\"external\">Vaccine Adverse Event Reporting System</a> (telephone number 1-800-822-7967) [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=standard-immunizations-for-children-and-adolescents-overview#H8\" class=\"medical medical_review\">&quot;Standard immunizations for children and adolescents: Overview&quot;, section on 'Reporting adverse events'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Porcine circovirus contamination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In 2010, an academic group using a novel technique found components of porcine circovirus (PCV1) in RV1 and the US Food and Drug Administration (FDA) temporarily suspended use of RV1 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/163\" class=\"abstract_t\">163</a>]. Additional review by the FDA and vaccine manufacturers determined that PCV1 components were present from the early stages of RV1 development, including during the prelicensure clinical trials, and that RV5 contained components of PCV1 and PCV2 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/163,164\" class=\"abstract_t\">163,164</a>].</p><p>Given that PCV1 and PCV2 are not known to cause illness in humans, and the absence of any evidence that millions of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> recipients suffered adverse effects related to PCV, the FDA recommended resumption of use of RV1 and continued use of RV5 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/164,165\" class=\"abstract_t\">164,165</a>]. In a subsequent observational study, PCV1 did not appear to replicate in RV1 recipients [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/166\" class=\"abstract_t\">166</a>].</p><p>The known benefits of the oral vaccination outweigh the theoretic risk related to PCV1 or PCV2 [<a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/167\" class=\"abstract_t\">167</a>].</p><p class=\"headingAnchor\" id=\"H3802603\"><span class=\"h1\">RESOURCES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resources related to immunization in infants include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www2.aap.org/immunization/&amp;token=5tltgKjsh1mDbJyHG0NEojtvXxoObTwUE4bhWW2y6R5PmFJ4GgdEW+OFRbHHZuzi&amp;TOPIC_ID=6023\" target=\"_blank\" class=\"external\">American Academy of Pediatrics</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.cdc.gov/vaccines/&amp;token=mjmpv7xMHRIW2nr+3NCnsVenaPhxrz3cZzbsuQzskhXf9B8M4Wsq4Jg16LNebxEp&amp;TOPIC_ID=6023\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.immunize.org/&amp;token=Xhpv4YrGbNrLf4iLM2FgO9OU7+srHa6FtzbbO0PYVVSvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=6023\" target=\"_blank\" class=\"external\">Immunization Action Coalition</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.cdc.gov/vaccines/pubs/vis/#rota&amp;token=mjmpv7xMHRIW2nr+3NCnsTubP6YtVyki9h+Z03HFKkB+lg/lmbI3K+ve4LwXkuA2c4X/1SDWGJcd674Z3QHYZQ==&amp;TOPIC_ID=6023\" target=\"_blank\" class=\"external\">Vaccine Information Statement for Rotavirus vaccine</a></p><p/><p class=\"headingAnchor\" id=\"H3184537479\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-immunizations-in-children-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Immunizations in children and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=rotavirus-infection-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Rotavirus infection (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topic (see <a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rotavirus is the most common cause of severe gastroenteritis in infants and children around the world. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two oral vaccines are available for the prevention of rotavirus disease: pentavalent human-bovine reassortant <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> (RV5, PRV, RotaTeq) and attenuated human rotavirus vaccine (RV1, HRV, Rotarix) (<a href=\"image.htm?imageKey=PEDS%2F70478\" class=\"graphic graphic_table graphicRef70478 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F89607\" class=\"graphic graphic_figure graphicRef89607 \">figure 2</a>). The vaccines have similar efficacy and safety, and neither vaccine is preferred over the other. (See <a href=\"#H59637410\" class=\"local\">'Rotavirus vaccines'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend universal immunization of infants against rotavirus (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). Rotavirus vaccines are highly effective in preventing rotavirus gastroenteritis and rotavirus gastroenteritis-associated hospitalization and health care utilization. (See <a href=\"#H73761146\" class=\"local\">'Indications'</a> above and <a href=\"#H3799903\" class=\"local\">'Efficacy/effectiveness'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contraindications to <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> include allergy to any of the vaccine ingredients, severe allergic reaction (anaphylaxis) to a previous dose, severe combined immunodeficiency (SCID), certain other primary and secondary immunodeficiencies, and history of intussusception. RV1 is contraindicated in infants with a history of severe allergic reaction to latex, but RV5 may be administered to such infants. (See <a href=\"#H3800611\" class=\"local\">'Contraindications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conditions that are precautions for administration of <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a> include immunodeficiency other than SCID, acute moderate or severe illness, certain pre-existing or acquired gastrointestinal conditions (eg, congenital malabsorption syndromes, Hirschsprung disease, short-bowel syndrome, previous bowel surgery), and spina bifida or bladder exstrophy. (See <a href=\"#H3800659\" class=\"local\">'Precautions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The recommended dose and schedule for RV5 and RV1 differ (<a href=\"image.htm?imageKey=PEDS%2F70478\" class=\"graphic graphic_table graphicRef70478 \">table 1</a>). Whenever possible, the vaccine series should be completed with the same product; however, vaccination should not be deferred if the product used for previous doses is not known. (See <a href=\"#H6\" class=\"local\">'Schedule'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intussusception is a rare potential adverse effect of oral rotavirus vaccination; however, the risk of intussusception after rotavirus vaccination is much lower than the risk of severe rotavirus gastroenteritis in children who do not receive <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>. (See <a href=\"#H9\" class=\"local\">'Adverse events and safety'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/1\" class=\"nounderline abstract_t\">Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58:1.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/2\" class=\"nounderline abstract_t\">Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565.</a></li><li class=\"breakAll\">World Health Organization. Rotavirus vaccines. WHO position paper - January 2013. http://www.who.int/wer/2013/wer8805.pdf (Accessed on February 19, 2013).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/4\" class=\"nounderline abstract_t\">Loharikar A, Dumolard L, Chu S, et al. Status of New Vaccine Introduction - Worldwide, September 2016. MMWR Morb Mortal Wkly Rep 2016; 65:1136.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/5\" class=\"nounderline abstract_t\">Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J Infect 2002; 45:1.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/6\" class=\"nounderline abstract_t\">Conner ME, Matson DO, Estes MK. Rotavirus vaccines and vaccination potential. Curr Top Microbiol Immunol 1994; 185:285.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/7\" class=\"nounderline abstract_t\">Vesikari T. Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Ann Med 1999; 31:79.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/8\" class=\"nounderline abstract_t\">Glass RI, Parashar UD. The promise of new rotavirus vaccines. N Engl J Med 2006; 354:75.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/9\" class=\"nounderline abstract_t\">Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/10\" class=\"nounderline abstract_t\">Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014; 383:2136.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/11\" class=\"nounderline abstract_t\">Blutt SE, Warfield KL, Estes MK, Conner ME. Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity. J Virol 2008; 82:3135.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/12\" class=\"nounderline abstract_t\">Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr Infect Dis J 2015; 34:635.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Rotavirus infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.684.</li><li class=\"breakAll\">RotaTeq (Rotavirus vaccine, live, oral, pentavalent). United States Prescribing Information. Revised February 2017, US Food &amp; Drug Administration. Available online at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm (Accessed on March 07, 2017).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/15\" class=\"nounderline abstract_t\">De Vos B, Han HH, Bouckenooghe A, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr Infect Dis J 2009; 28:261.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/16\" class=\"nounderline abstract_t\">Santosham M, Steele D. Rotavirus Vaccines - A New Hope. N Engl J Med 2017; 376:1170.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/17\" class=\"nounderline abstract_t\">Mi K, Ou X, Guo L, et al. Comparative analysis of the immunogenicity of monovalent and multivalent rotavirus immunogens. PLoS One 2017; 12:e0172156.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/18\" class=\"nounderline abstract_t\">Zhen SS, Li Y, Wang SM, et al. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg Microbes Infect 2015; 4:e64.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/19\" class=\"nounderline abstract_t\">Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 2011; 203:188.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/20\" class=\"nounderline abstract_t\">Isanaka S, Guindo O, Langendorf C, et al. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. N Engl J Med 2017; 376:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/21\" class=\"nounderline abstract_t\">Bines JE, At Thobari J, Satria CD, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. N Engl J Med 2018; 378:719.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/22\" class=\"nounderline abstract_t\">Bines JE, Danchin M, Jackson P, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015; 15:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/23\" class=\"nounderline abstract_t\">Recommended childhood immunization schedule-United States, January-December 1999. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1999; 103:182.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/24\" class=\"nounderline abstract_t\">Peter G, Myers MG, National Vaccine Advisory Committee, National Vaccine Program Office. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002; 110:e67.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/25\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:577.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/26\" class=\"nounderline abstract_t\">Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/27\" class=\"nounderline abstract_t\">Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003; 187:1301.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/28\" class=\"nounderline abstract_t\">Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/29\" class=\"nounderline abstract_t\">Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012; 11:CD008521.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/30\" class=\"nounderline abstract_t\">Ruiz-Palacios GM, P&eacute;rez-Schael I, Vel&aacute;zquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/31\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010; 59:687.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/32\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR Morb Mortal Wkly Rep 2011; 60:1427.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/33\" class=\"nounderline abstract_t\">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/34\" class=\"nounderline abstract_t\">Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/35\" class=\"nounderline abstract_t\">Werther RL, Crawford NW, Boniface K, et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009; 124:600.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/36\" class=\"nounderline abstract_t\">Bakare N, Menschik D, Tiernan R, et al. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010; 28:6609.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/37\" class=\"nounderline abstract_t\">Kaplon J, Cros G, Ambert-Balay K, et al. Rotavirus vaccine virus shedding, viremia and clearance in infants with severe combined immune deficiency. Pediatr Infect Dis J 2015; 34:326.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/38\" class=\"nounderline abstract_t\">Morillo-Gutierrez B, Worth A, Valappil M, et al. Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency. Pediatr Infect Dis J 2015; 34:1040.</a></li><li class=\"breakAll\">MedWatch. The FDA safety information and adverse event reporting program. Drug safety labeling changes. Rotarix (rotavirus vaccine, live, oral) oral suspension. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm230397.htm (Accessed on April 18, 2011).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/40\" class=\"nounderline abstract_t\">Goveia MG, DiNubile MJ, Dallas MJ, et al. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008; 27:656.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/41\" class=\"nounderline abstract_t\">Vesikari T, Prymula R, Schuster V, et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J 2012; 31:509.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/42\" class=\"nounderline abstract_t\">Groome MJ, Madhi SA. Five-year cohort study on the burden of hospitalisation for acute diarrhoeal disease in African HIV-infected and HIV-uninfected children: potential benefits of rotavirus vaccine. Vaccine 2012; 30 Suppl 1:A173.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/43\" class=\"nounderline abstract_t\">Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. Pediatr Infect Dis J 2011; 30:125.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/44\" class=\"nounderline abstract_t\">Levin MJ, Lindsey JC, Kaplan SS, et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS 2017; 31:49.</a></li><li class=\"breakAll\">Department of Health and Human Services. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Available at: aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf (Accessed on November 20, 2013).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/46\" class=\"nounderline abstract_t\">Javid PJ, Sanchez SE, Jacob S, et al. The Safety and Immunogenicity of Rotavirus Vaccination in Infants With Intestinal Failure. J Pediatric Infect Dis Soc 2014; 3:57.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/47\" class=\"nounderline abstract_t\">McGrath EJ, Thomas R, Duggan C, Asmar BI. Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease. J Pediatr Gastroenterol Nutr 2014; 59:44.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/48\" class=\"nounderline abstract_t\">Libster R, McNeal M, Walter EB, et al. Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics 2016; 137:e20152603.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/49\" class=\"nounderline abstract_t\">Payne DC, Sulemana I, Parashar UD, New Vaccine Surveillance Network. Evaluation of Effectiveness of Mixed Rotavirus Vaccine Course for Rotavirus Gastroenteritis. JAMA Pediatr 2016; 170:708.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/50\" class=\"nounderline abstract_t\">Payne DC, Selvarangan R, Azimi PH, et al. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013. Clin Infect Dis 2015; 61:1792.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/51\" class=\"nounderline abstract_t\">Goveia MG, Suprun L, Itzler RF, et al. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatr Infect Dis J 2010; 29:263.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/52\" class=\"nounderline abstract_t\">Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007; 26:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/53\" class=\"nounderline abstract_t\">Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31:487.</a></li><li class=\"breakAll\">Rotavirus. In Australian Immunisation Handbook, 10th edition. Available at:http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-17#4.17.6 (Accessed on January 08, 2018).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/55\" class=\"nounderline abstract_t\">Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics 2014; 133:e1555.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/56\" class=\"nounderline abstract_t\">Thrall S, Doll MK, Nhan C, et al. Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. Vaccine 2015; 33:5095.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/57\" class=\"nounderline abstract_t\">Hofstetter AM, Lacombe K, Klein EJ, et al. Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Pediatrics 2018; 141.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/58\" class=\"nounderline abstract_t\">Hiramatsu H, Suzuki R, Nagatani A, et al. Rotavirus Vaccination Can Be Performed Without Viral Dissemination in the Neonatal Intensive Care Unit. J Infect Dis 2018; 217:589.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/59\" class=\"nounderline abstract_t\">Vel&aacute;zquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022.</a></li><li class=\"breakAll\">Kroger AT, Duchin J, V&aacute;zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on April 27, 2017).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/61\" class=\"nounderline abstract_t\">Abeid KA, Jani B, Cortese MM, et al. Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years After Introduction. J Infect Dis 2017; 215:183.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/62\" class=\"nounderline abstract_t\">Narv&aacute;ez J, Osorio MB, Casta&ntilde;eda-Orjuela C, et al. Is Colombia reaching the goals on infant immunization coverage? A quantitative survey from 80 municipalities. Vaccine 2017; 35:1501.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/63\" class=\"nounderline abstract_t\">Bennett A, Bar-Zeev N, Cunliffe NA. Measuring indirect effects of rotavirus vaccine in low income countries. Vaccine 2016; 34:4351.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/64\" class=\"nounderline abstract_t\">Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. Malawi Med J 2016; 28:108.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/65\" class=\"nounderline abstract_t\">Vel&aacute;zquez RF, Linhares AC, Mu&ntilde;oz S, et al. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr 2017; 17:14.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/66\" class=\"nounderline abstract_t\">Gruber JF, Hille DA, Liu GF, et al. Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries. Pediatr Infect Dis J 2017; 36:72.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/67\" class=\"nounderline abstract_t\">Wylie KM, Stanley KM, TeKippe EM, et al. Resurgence of Rotavirus Genotype G12 in St. Louis During the 2014-2015 Rotavirus Season. J Pediatric Infect Dis Soc 2017; 6:346.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/68\" class=\"nounderline abstract_t\">Muhsen K, Kassem E, Rubenstein U, et al. Incidence of rotavirus gastroenteritis hospitalizations and genotypes, before and five years after introducing universal immunization in Israel. Vaccine 2016; 34:5916.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/69\" class=\"nounderline abstract_t\">Lo Vecchio A, Liguoro I, Dias JA, et al. Rotavirus immunization: Global coverage and local barriers for implementation. Vaccine 2017; 35:1637.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/70\" class=\"nounderline abstract_t\">Tissera MS, Cowley D, Bogdanovic-Sakran N, et al. Options for improving effectiveness of rotavirus vaccines in developing countries. Hum Vaccin Immunother 2017; 13:921.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/71\" class=\"nounderline abstract_t\">Al-Aidaroos AYA, Standaert B, Meszaros K, Shibl AM. Economic assessment of rotavirus vaccination in Saudi Arabia. J Infect Public Health 2017; 10:564.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/72\" class=\"nounderline abstract_t\">Hill HA, Elam-Evans LD, Yankey D, et al. Vaccination Coverage Among Children Aged 19-35 Months - United States, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/73\" class=\"nounderline abstract_t\">Gosselin V, Petit G, Gagneur A, G&eacute;n&eacute;reux M. Trends in severe gastroenteritis among young children according to socio-economic characteristics before and after implementation of a rotavirus vaccination program in Quebec. Can J Public Health 2016; 107:e161.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/74\" class=\"nounderline abstract_t\">Burnett E, Jonesteller CL, Tate JE, et al. Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea. J Infect Dis 2017; 215:1666.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/75\" class=\"nounderline abstract_t\">Jonesteller CL, Burnett E, Yen C, et al. Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016. Clin Infect Dis 2017; 65:840.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/76\" class=\"nounderline abstract_t\">Loganathan T, Jit M, Hutubessy R, et al. Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system. Trop Med Int Health 2016; 21:1458.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/77\" class=\"nounderline abstract_t\">Santos VS, Marques DP, Martins-Filho PR, et al. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infect Dis Poverty 2016; 5:83.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/78\" class=\"nounderline abstract_t\">Holubar M, Stavroulakis MC, Maldonado Y, et al. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS One 2017; 12:e0172414.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/79\" class=\"nounderline abstract_t\">Markkula J, Hemming-Harlo M, Salminen MT, et al. Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly. Infect Dis (Lond) 2017; 49:388.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/80\" class=\"nounderline abstract_t\">da Silva MF, Fumian TM, de Assis RM, et al. VP7 and VP8* genetic characterization of group A rotavirus genotype G12P[8]: Emergence and spreading in the Eastern Brazilian coast in 2014. J Med Virol 2017; 89:64.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/81\" class=\"nounderline abstract_t\">Asada K, Kamiya H, Suga S, et al. Rotavirus vaccine and health-care utilization for rotavirus gastroenteritis in Tsu City, Japan. Western Pac Surveill Response J 2016; 7:28.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/82\" class=\"nounderline abstract_t\">Rogawski ET, Platts-Mills JA, Colgate ER, et al. Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study. J Infect Dis 2018; 217:861.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/83\" class=\"nounderline abstract_t\">Mwila K, Chilengi R, Simuyandi M, et al. Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries. Clin Vaccine Immunol 2017; 24.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/84\" class=\"nounderline abstract_t\">Bautista-Marquez A, Velasquez DE, Esparza-Aguilar M, et al. Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix&reg; immunization in Mexican infants. Vaccine 2016; 34:5284.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/85\" class=\"nounderline abstract_t\">Becker-Dreps S, Vilchez S, Bucardo F, et al. The Association Between Fecal Biomarkers of Environmental Enteropathy and Rotavirus Vaccine Response in Nicaraguan Infants. Pediatr Infect Dis J 2017; 36:412.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/86\" class=\"nounderline abstract_t\">Harris VC, Armah G, Fuentes S, et al. Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana. J Infect Dis 2017; 215:34.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/87\" class=\"nounderline abstract_t\">Hibbs BF, Miller ER, Shimabukuro T, Centers for Disease Control and Prevention (CDC). Notes from the field: rotavirus vaccine administration errors--United States, 2006-2013. MMWR Morb Mortal Wkly Rep 2014; 63:81.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/88\" class=\"nounderline abstract_t\">Groome MJ, Moon SS, Velasquez D, et al. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 2014; 92:238.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/89\" class=\"nounderline abstract_t\">Rongsen-Chandola T, Strand TA, Goyal N, et al. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine 2014; 32 Suppl 1:A134.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/90\" class=\"nounderline abstract_t\">Ali A, Kazi AM, Cortese MM, et al. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine--a randomized trial. PLoS One 2015; 10:e0127622.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/91\" class=\"nounderline abstract_t\">Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007; 26:221.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/92\" class=\"nounderline abstract_t\">Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009; 28:177.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/93\" class=\"nounderline abstract_t\">Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30:e103.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/94\" class=\"nounderline abstract_t\">Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008; 27:874.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/95\" class=\"nounderline abstract_t\">Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010; 28:6542.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/96\" class=\"nounderline abstract_t\">Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/97\" class=\"nounderline abstract_t\">Aliabadi N, Tate JE, Haynes AK, et al. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination&mdash;United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2015; 64:337.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/98\" class=\"nounderline abstract_t\">Leshem E, Tate JE, Steiner CA, et al. Acute gastroenteritis hospitalizations among US children following implementation of the rotavirus vaccine. JAMA 2015; 313:2282.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/99\" class=\"nounderline abstract_t\">Kaufman HW, Chen Z. Trends in Laboratory Rotavirus Detection: 2003 to 2014. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/100\" class=\"nounderline abstract_t\">Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatr Infect Dis J 2012; 31:184.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/101\" class=\"nounderline abstract_t\">Lamberti LM, Ashraf S, Walker CL, Black RE. A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 Years. Pediatr Infect Dis J 2016; 35:992.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/102\" class=\"nounderline abstract_t\">Vesikari T, Karvonen A, Ferrante SA, et al. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010; 29:957.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/103\" class=\"nounderline abstract_t\">Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children &lt;5 years of age, 2009-2011. Clin Infect Dis 2013; 57:13.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/104\" class=\"nounderline abstract_t\">Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007-2011). Pediatrics 2014; 134:15.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/105\" class=\"nounderline abstract_t\">Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/106\" class=\"nounderline abstract_t\">Salinas B, P&eacute;rez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/107\" class=\"nounderline abstract_t\">De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004; 23:S179.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/108\" class=\"nounderline abstract_t\">Ruiz-Palacios GM, Guerrero ML, Bautista-M&aacute;rquez A, et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics 2007; 120:e253.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/109\" class=\"nounderline abstract_t\">Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/110\" class=\"nounderline abstract_t\">Linhares AC, Vel&aacute;zquez FR, P&eacute;rez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/111\" class=\"nounderline abstract_t\">Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013; 132:e25.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/112\" class=\"nounderline abstract_t\">Immergluck LC, Parker TC, Jain S, et al. Sustained Effectiveness of Monovalent and Pentavalent Rotavirus&nbsp;Vaccines in Children. J Pediatr 2016; 172:116.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/113\" class=\"nounderline abstract_t\">Payne DC, Baggs J, Zerr DM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis 2014; 58:173.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/114\" class=\"nounderline abstract_t\">Pardo-Seco J, Cebey-L&oacute;pez M, Martin&oacute;n-Torres N, et al. Impact of Rotavirus Vaccination on Childhood Hospitalization for Seizures. Pediatr Infect Dis J 2015; 34:769.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/115\" class=\"nounderline abstract_t\">Sheridan SL, Ware RS, Grimwood K, Lambert SB. Febrile Seizures in the Era of Rotavirus Vaccine. J Pediatric Infect Dis Soc 2016; 5:206.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/116\" class=\"nounderline abstract_t\">Pringle KD, Burke RM, Steiner CA, et al. Trends in Rate of Seizure-Associated Hospitalizations Among Children &lt;5 Years Old Before and After Rotavirus Vaccine Introduction in the United Sates, 2000-2013. J Infect Dis 2018; 217:581.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/117\" class=\"nounderline abstract_t\">Atchison CJ, Stowe J, Andrews N, et al. Rapid Declines in Age Group-Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales. J Infect Dis 2016; 213:243.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/118\" class=\"nounderline abstract_t\">Tate JE, Haynes A, Payne DC, et al. Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000 to 2012. Pediatr Infect Dis J 2013; 32:741.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/119\" class=\"nounderline abstract_t\">Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011; 204:980.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/120\" class=\"nounderline abstract_t\">Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53:245.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/121\" class=\"nounderline abstract_t\">Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust 2012; 197:453.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/122\" class=\"nounderline abstract_t\">Lopman BA, Payne DC, Tate JE, et al. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol 2012; 2:434.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/123\" class=\"nounderline abstract_t\">Anderson EJ, Shippee DB, Weinrobe MH, et al. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis 2013; 56:755.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/124\" class=\"nounderline abstract_t\">Gasta&ntilde;aduy PA, Curns AT, Parashar UD, Lopman BA. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. JAMA 2013; 310:851.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/125\" class=\"nounderline abstract_t\">Cortese MM, Dahl RM, Curns AT, Parashar UD. Protection against gastroenteritis in US households with children who received rotavirus vaccine. J Infect Dis 2015; 211:558.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/126\" class=\"nounderline abstract_t\">Mast TC, Wang FT, Su S, Seeger JD. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. Pediatr Infect Dis J 2015; 34:615.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/127\" class=\"nounderline abstract_t\">Prelog M, Gorth P, Zwazl I, et al. Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination. J Infect Dis 2016; 214:546.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/128\" class=\"nounderline abstract_t\">Patel MM, L&oacute;pez-Collada VR, Bulh&otilde;es MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/129\" class=\"nounderline abstract_t\">Vel&aacute;zquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012; 31:736.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/130\" class=\"nounderline abstract_t\">Haber P, Patel M, Pan Y, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics 2013; 131:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/131\" class=\"nounderline abstract_t\">Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013; 57:1427.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/132\" class=\"nounderline abstract_t\">Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014; 370:513.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/133\" class=\"nounderline abstract_t\">Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014; 370:503.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/134\" class=\"nounderline abstract_t\">Leino T, Ollgren J, Str&ouml;mberg N, Elonsalo U. Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants. PLoS One 2016; 11:e0144812.</a></li><li class=\"breakAll\">Rotarix (Rotavirus vaccine, live, oral) prescribing information, 2011. http://us.gsk.com/products/assets/us_rotarix.pdf (Accessed on April 21, 2011).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Vaccine Safety. Rotavirus. http://www.cdc.gov/vaccinesafety/vaccines/rotavsb.html (Accessed on September 04, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Rotarix&reg; rotavirus vaccine: Rare side effect possible. Questions and answers for parents and caregivers. http://www.cdc.gov/vaccines/vpd-vac/rotavirus/Vac-label-parents.htm (Accessed on September 23, 2010).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/138\" class=\"nounderline abstract_t\">Desai R, Cortese MM, Meltzer MI, et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J 2013; 32:1.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/139\" class=\"nounderline abstract_t\">Glass RI, Parashar UD. Rotavirus vaccines--balancing intussusception risks and health benefits. N Engl J Med 2014; 370:568.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/140\" class=\"nounderline abstract_t\">Buttery JP, Standish J, Bines JE. Intussusception and rotavirus vaccines: consensus on benefits outweighing recognized risk. Pediatr Infect Dis J 2014; 33:772.</a></li><li class=\"breakAll\">U.S. Food and Drug Administration. Information on Rotarix--Labeling revision pertaining to intussusception. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm226690.htm (Accessed on September 23, 2010).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/142\" class=\"nounderline abstract_t\">Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012; 307:598.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/143\" class=\"nounderline abstract_t\">Tate JE, Yen C, Steiner CA, et al. Intussusception Rates Before and After the Introduction of Rotavirus Vaccine. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/144\" class=\"nounderline abstract_t\">DeStefano F, Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 2001; 10:403.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/145\" class=\"nounderline abstract_t\">Warfield KL, Blutt SE, Crawford SE, et al. Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse model. J Virol 2006; 80:12377.</a></li><li class=\"breakAll\">RotaTeq&reg; [Rotavirus Vaccine, Live, Oral, Pentavalent] product label http://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf (Accessed on August 02, 2011).</li><li class=\"breakAll\">Information pertaining to labeling revision for RotaTeq http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm142393.htm (Accessed on August 02, 2011).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/148\" class=\"nounderline abstract_t\">Loughlin J, Mast TC, Doherty MC, et al. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012; 31:292.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/149\" class=\"nounderline abstract_t\">Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007; 11 Suppl 2:S36.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/150\" class=\"nounderline abstract_t\">Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008; 8:642.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/151\" class=\"nounderline abstract_t\">Matson DO, Vesikari T, Dennehy P, et al. Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Hum Vaccin Immunother 2014; 10:2267.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/152\" class=\"nounderline abstract_t\">Uygungil B, Bleesing JJ, Risma KA, et al. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol 2010; 125:270.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/153\" class=\"nounderline abstract_t\">Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010; 125:e438.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/154\" class=\"nounderline abstract_t\">Hemming M, Vesikari T. Detection of rotateq vaccine-derived, double-reassortant rotavirus in a 7-year-old child with acute gastroenteritis. Pediatr Infect Dis J 2014; 33:655.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/155\" class=\"nounderline abstract_t\">Sakon N, Miyamoto R, Komano J. An infant with acute gastroenteritis caused by a secondary infection with a Rotarix-derived strain. Eur J Pediatr 2017; 176:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/156\" class=\"nounderline abstract_t\">Rivera L, Pe&ntilde;a LM, Stainier I, et al. Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins. Vaccine 2011; 29:9508.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Rotavirus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on July 09, 2015).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/158\" class=\"nounderline abstract_t\">Al-Ayed MS, Asaad AM, Qureshi MA, Hawan AA. Epidemiology of group A rotavirus infection after the introduction of monovalent vaccine in the National Immunization Program of Saudi Arabia. J Med Virol 2017; 89:429.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/159\" class=\"nounderline abstract_t\">Zeller M, Heylen E, Tamim S, et al. Comparative analysis of the Rotarix&trade; vaccine strain and G1P[8] rotaviruses detected before and after vaccine introduction in Belgium. PeerJ 2017; 5:e2733.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/160\" class=\"nounderline abstract_t\">Mukhopadhya I, Murdoch H, Berry S, et al. Changing molecular epidemiology of rotavirus infection after introduction of monovalent rotavirus vaccination in Scotland. Vaccine 2017; 35:156.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/161\" class=\"nounderline abstract_t\">Bowen MD, Mijatovic-Rustempasic S, Esona MD, et al. Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013. J Infect Dis 2016; 214:732.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/162\" class=\"nounderline abstract_t\">Roczo-Farkas S, Kirkwood CD, Bines JE, and the Australian Rotavirus Surveillance Group. Australian Rotavirus Surveillance Program annual report, 2015. Commun Dis Intell Q Rep 2016; 40:E527.</a></li><li class=\"breakAll\">US Food and Drug Administration. Components of extraneous virus detected in Rotarix vaccine; no known safety risk www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm205625.htm (Accessed on March 22, 2010).</li><li class=\"breakAll\">U.S. Food and Drug Administration. Update on recommendations for the use of rotavirus vaccines. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm212140.htm (Accessed on May 17, 2010).</li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/165\" class=\"nounderline abstract_t\">Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010; 84:6033.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/166\" class=\"nounderline abstract_t\">Mijatovic-Rustempasic S, Immergluck LC, Parker TC, et al. Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix&reg;. Hum Vaccin Immunother 2017; 13:928.</a></li><li><a href=\"https://www.uptodate.com/contents/rotavirus-vaccines-for-infants/abstract/167\" class=\"nounderline abstract_t\">Kuehn BM. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010; 304:30.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6023 Version 56.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3802518\" id=\"outline-link-H3802518\">MICROBIOLOGY</a></li><li><a href=\"#H59637410\" id=\"outline-link-H59637410\">ROTAVIRUS VACCINES</a><ul><li><a href=\"#H187918050\" id=\"outline-link-H187918050\">Vaccine development</a></li><li><a href=\"#H187918043\" id=\"outline-link-H187918043\">Vaccines licensed in the United States</a></li><li><a href=\"#H183587254\" id=\"outline-link-H183587254\">Other vaccines</a></li></ul></li><li><a href=\"#H73761146\" id=\"outline-link-H73761146\">INDICATIONS</a></li><li><a href=\"#H3800611\" id=\"outline-link-H3800611\">CONTRAINDICATIONS</a></li><li><a href=\"#H3800659\" id=\"outline-link-H3800659\">PRECAUTIONS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">SCHEDULE</a><ul><li><a href=\"#H500915636\" id=\"outline-link-H500915636\">Routine schedule</a></li><li><a href=\"#H500915643\" id=\"outline-link-H500915643\">Catch-up schedule</a></li><li><a href=\"#H500915613\" id=\"outline-link-H500915613\">Special circumstances</a><ul><li><a href=\"#H500915621\" id=\"outline-link-H500915621\">- Premature infants</a></li><li><a href=\"#H500915629\" id=\"outline-link-H500915629\">- Infants with rotavirus gastroenteritis</a></li><li><a href=\"#H3801215\" id=\"outline-link-H3801215\">- Receipt of blood products</a></li><li><a href=\"#H3802185\" id=\"outline-link-H3802185\">- Hospitalization of vaccinated infant</a></li><li><a href=\"#H3802933\" id=\"outline-link-H3802933\">- Immunocompromised household contact</a></li><li><a href=\"#H3927504007\" id=\"outline-link-H3927504007\">- Resource-poor countries with high child mortality</a></li></ul></li></ul></li><li><a href=\"#H3803151\" id=\"outline-link-H3803151\">ADMINISTRATION</a></li><li><a href=\"#H3803158\" id=\"outline-link-H3803158\">ADMINISTRATION WITH OTHER VACCINES</a></li><li><a href=\"#H3799903\" id=\"outline-link-H3799903\">EFFICACY/EFFECTIVENESS</a><ul><li><a href=\"#H3799910\" id=\"outline-link-H3799910\">Rotavirus gastroenteritis</a></li><li><a href=\"#H1305954013\" id=\"outline-link-H1305954013\">Reduced risk of seizures</a></li><li><a href=\"#H3799917\" id=\"outline-link-H3799917\">Community (&quot;herd&quot;) immunity</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">ADVERSE EVENTS AND SAFETY</a><ul><li><a href=\"#H73761326\" id=\"outline-link-H73761326\">Overview</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Intussusception</a><ul><li><a href=\"#H3801443\" id=\"outline-link-H3801443\">- Risk with RV5 and RV1</a></li><li><a href=\"#H3801876\" id=\"outline-link-H3801876\">- Risk with RRV-TV</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">Kawasaki disease</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Shedding and transmission of vaccine virus</a></li><li><a href=\"#H4184606107\" id=\"outline-link-H4184606107\">G serotype substitution</a></li><li><a href=\"#H3803400\" id=\"outline-link-H3803400\">Reporting adverse events</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Porcine circovirus contamination</a></li></ul></li><li><a href=\"#H3802603\" id=\"outline-link-H3802603\">RESOURCES</a></li><li><a href=\"#H3184537479\" id=\"outline-link-H3184537479\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H25\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6023|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/89606\" class=\"graphic graphic_figure\">- Rotavirus</a></li><li><a href=\"image.htm?imageKey=PEDS/89607\" class=\"graphic graphic_figure\">- Rotavirus vaccines</a></li><li><a href=\"image.htm?imageKey=PEDS/58821\" class=\"graphic graphic_figure\">- Rotavirus activity in US before and after rotavirus vaccine </a></li></ul></li><li><div id=\"PEDS/6023|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/70478\" class=\"graphic graphic_table\">- Rotavirus vaccines summary</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-viral-gastroenteritis-in-children-in-resource-rich-countries-management-and-prevention\" class=\"medical medical_review\">Acute viral gastroenteritis in children in resource-rich countries: Management and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=allergic-reactions-to-vaccines\" class=\"medical medical_review\">Allergic reactions to vaccines</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chediak-higashi-syndrome\" class=\"medical medical_review\">Chediak-Higashi syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-granulomatous-disease-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-rotavirus-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of rotavirus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">Combined immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-neutropenia\" class=\"medical medical_review\">Congenital neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cyclic-neutropenia\" class=\"medical medical_review\">Cyclic neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inherited-disorders-of-the-complement-system\" class=\"medical medical_review\">Inherited disorders of the complement system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intussusception-in-children\" class=\"medical medical_review\">Intussusception in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=kawasaki-disease-clinical-features-and-diagnosis\" class=\"medical medical_review\">Kawasaki disease: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=leukocyte-adhesion-deficiency\" class=\"medical medical_review\">Leukocyte-adhesion deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rotavirus-infection-the-basics\" class=\"medical medical_basics\">Patient education: Rotavirus infection (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-humoral-immunodeficiencies-an-overview\" class=\"medical medical_review\">Primary humoral immunodeficiencies: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-iga-deficiency-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=severe-combined-immunodeficiency-scid-an-overview\" class=\"medical medical_review\">Severe combined immunodeficiency (SCID): An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-immunizations-in-children-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Immunizations in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=specific-antibody-deficiency\" class=\"medical medical_review\">Specific antibody deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=standard-immunizations-for-children-and-adolescents-overview\" class=\"medical medical_review\">Standard immunizations for children and adolescents: Overview</a></li></ul></div></div>","javascript":null}